Cerevel Therapeutics (CERE) Financial Analysis & Valuation | Quarter Chart
Cerevel Therapeutics (CERE)
CEREPrice: $44.96
Fair Value: 🔒
🔒score
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and ... more
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the deve... more
Description
Shares
| Market Cap | $8.19B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Ronald C. Renaud Jr., |
| IPO Date | 2020-07-30 | CAGR | — |
| Employees | 355 | Website | www.cerevel.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CERE chart loading...
Fundamentals
Technicals
| Enterprise Value | $7.73B | P/E Ratio | -16.47 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 10.81 |
| P/CF Ratio | -21.29 | P/FCF Ratio | -23.67 |
| EPS | $-2.73 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.72% | ROA | -0.35% |
| ROCE | -0.39% | Current Ratio | 10.92 |
| Quick Ratio | 10.92 | Cash Ratio | 10.75 |
| Debt/Equity | 0.71 | Interest Coverage | -42.33 |
| Altman Z Score | 6.31 | Piotroski Score | 3 |